Move over COVID, Tuberculosis Is Once again the Leading Cause of Death from a Single Infectious Disease

IF 6.8 1区医学 Q1 CHEMISTRY, MEDICINAL

Journal of Medicinal Chemistry Pub Date : 2024-12-09 DOI:10.1021/acs.jmedchem.4c02876

Tomayo Berida, Craig W. Lindsley

引用次数: 0

Abstract

Figure 1. Antitubercular drugs in clinical use. (3,4) Table one was adapted from WHO’s 2023 Antibacterial agents in clinical and preclinical development. (16) NCR: No cross resistance, NCC: New chemical class; NT: New target; MoA: New mechanism of Action. Figure 2. Antitubercular agent in clinical development. Figure 3. Cell wall of mycobacteria (left), Gram-positive bacteria (center), and Gram-negative bacteria (right). The figure was adapted from “Plant Antibacterials: The Challenges and Opportunities”, Berida et al, Heliyon 2024, 10 (10), e31145, with permission from Elsevier. (26) This article references 38 other publications. This article has not yet been cited by other publications.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medicinal Chemistry 医学-医药化学

CiteScore

4.00

自引率

11.00%

发文量

804

审稿时长

1.9 months

期刊介绍： The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.